Novo Nordisk A/S (NVO) and The United Laboratories International Holdings Limited (TUL) on Wednesday announced positive topline results from a Phase 2 trial of UBT251, an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, for the treatment of type 2 diabetes.
The study evaluated UBT251 against placebo and semaglutide in patients with type 2 diabetes in China. UBT251 demonstrated a mean HbA1c reduction of up to 2.16% and a mean body weight reduction of up to 9.8% after 24 weeks, showing greater improvements compared to both placebo and semaglutide.
The safety and tolerability profile of UBT251 was consistent with what has been observed in other studies involving triple agonists.
UBT251 is being jointly developed by TUL's unit, The United Bio-Technology (Hengqin) Co., Ltd. and Novo Nordisk under an agreement signed in March 2025. United Biotechnology is responsible for development in Chinese mainland, Hong Kong, Macau and Taiwan, while Novo Nordisk is responsible for development in the rest of the world.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.